MIRMMirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next Mirum Pharmaceuticals reported second-quarter 2026 results showing a net loss of US$67.23 million (US$1.06 per share) and a six-month net loss of US$857.38 million (US$14.03 per share), while also updating investors on commercial progress and pipeline developments. Despite the very large year-on-year increase in net loss, Mirum raised its 2026 net product sales guidance, highlighted breakthrough therapy designation for volixibat, and outlined the potential US launch timing for Zilurgisertib,... | ||
 Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript LIVMARLI sales surged 46% while management raised full-year guidance to $680M–$700M. | ||
 Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath. Insmed stock led a biotech rally Thursday, catapulting 34% on solid second-quarter sales for its new lung disease drug, Brinsupri. | ||
 Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook. | ||
 Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15% The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program. | ||
 Mirum Pharmaceuticals Q2 Earnings Call Highlights Mirum Pharmaceuticals (NASDAQ:MIRM) reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfo | ||
 Mirum Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby summary of Mirum Pharmaceuticals, Inc.'s Q2 2026 earnings call | ||
 Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. | ||
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -3.90% and +6.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
IInsider Monkey | ||
IInsider Monkey | ||